Samsung Biologics and Pfizer collaborate for long-term manufacturing of biosimilars portfolio
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The company will manufacture a cancer immunotherapy product from 2022
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
The Congress was held on June, 20-21, 2022 in Berlin, Germany
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
Subscribe To Our Newsletter & Stay Updated